By Michele Maatouk
Date: Monday 20 Apr 2026
(Sharecast News) - Eli Lilly said on Monday that it has agreed to buy Boston-based Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery, for up to $7bn in cash.
| Currency | US Dollars |
| Share Price | $ 919.90 |
| Change Today | $ -7.13 |
| % Change | -0.77 % |
| 52 Week High | $1,109.94 |
| 52 Week Low | $625.65 |
| Volume | 2,671 |
| Shares Issued | 944.80m |
| Market Cap | $869,122m |
| RiskGrade | 179 |
| Strong Buy | 12 |
| Buy | 12 |
| Neutral | 7 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 31 |

| Time | Volume / Share Price |
| 16:00 | 325,920 @ $919.90 |
| 16:00 | 146 @ $920.59 |
| 16:00 | 40 @ $920.58 |
| 16:00 | 40 @ $920.40 |
| 16:00 | 50 @ $920.40 |
You are here: research